Coding Therapeutic Nucleic Acids from Recombinant Proteins to Next-Generation Vaccines: Current Uses, Limitations, and Future Horizons

This study aims to highlight the potential use of cTNAs in therapeutic applications. The COVID-19 pandemic has led to significant use of coding therapeutic nucleic acids (cTNAs) in terms of DNA and mRNA in the development of vaccines. The use of cTNAs resulted in a paradigm shift in the therapeutic...

Full description

Saved in:
Bibliographic Details
Published in:Molecular biotechnology 2024-08, Vol.66 (8), p.1853-1871
Main Authors: Harisa, Gamaleldin I., Faris, Tarek M., Sherif, Abdelrahman Y., Alzhrani, Riyad F., Alanazi, Saleh A., Kohaf, Neveen A., Alanazi, Fars K.
Format: Article
Language:English
Subjects:
Animals
Biochemistry
Biological effects
Biological Techniques
Biotechnology
Cancer therapies
Cancer vaccines
Cell Biology
Chemical modification
Chemistry
Chemistry and Materials Science
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines - immunology
Deoxyribonucleic acid
DNA
DNA vaccines
Drug delivery
Ebola virus
Genetic disorders
Human Genetics
Humans
Immunogenicity
Malaria
mRNA
Nucleic acids
Nucleic Acids - therapeutic use
Pandemics
Protein Science
Proteins
Public health
Recombinant Proteins - genetics
Recombinant Proteins - immunology
Respiratory syncytial virus
Review Paper
RNA, Messenger - genetics
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Therapeutic applications
Vaccine Development
Vaccines
Vector-borne diseases
Viral diseases
Viruses
Zika virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to highlight the potential use of cTNAs in therapeutic applications. The COVID-19 pandemic has led to significant use of coding therapeutic nucleic acids (cTNAs) in terms of DNA and mRNA in the development of vaccines. The use of cTNAs resulted in a paradigm shift in the therapeutic field. However, the injection of DNA or mRNA into the human body transforms cells into biological factories to produce the necessary proteins. Despite the success of cTNAs in the production of corona vaccines, they have several limitations such as instability, inability to cross biomembranes, immunogenicity, and the possibility of integration into the human genome. The chemical modification and utilization of smart drug delivery cargoes resolve cTNAs therapeutic problems. The success of cTNAs in corona vaccine production provides perspective for the eradication of influenza viruses, Zika virus, HIV, respiratory syncytial virus, Ebola virus, malaria, and future pandemics by quick vaccine design. Moreover, the progress cTNAs technology is promising for the development of therapy for genetic disease, cancer therapy, and currently incurable diseases. Graphical Abstract
ISSN:1073-6085
1559-0305
1559-0305
DOI:10.1007/s12033-023-00821-z